Amgen (NASDAQ:AMGN - Get Free Report) was upgraded by stock analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a research note issued to investors on Friday.
AMGN has been the subject of several other research reports. Wells Fargo & Company downgraded Amgen from an "overweight" rating to an "equal weight" rating and raised their target price for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Oppenheimer restated an "outperform" rating and issued a $380.00 price objective on shares of Amgen in a report on Wednesday, August 7th. Barclays raised their price target on Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research report on Monday, October 7th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $362.00 price objective on shares of Amgen in a research note on Thursday, September 26th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $333.50.
Check Out Our Latest Stock Report on Amgen
Amgen Trading Down 0.3 %
NASDAQ AMGN traded down $0.94 during trading hours on Friday, hitting $319.22. 1,826,745 shares of the company's stock were exchanged, compared to its average volume of 2,418,089. The firm has a market cap of $171.53 billion, a price-to-earnings ratio of 40.87, a PEG ratio of 2.84 and a beta of 0.61. Amgen has a 1-year low of $260.52 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. The stock has a 50-day simple moving average of $324.47 and a 200 day simple moving average of $315.19.
Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 181.58% and a net margin of 13.00%. The company's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period in the prior year, the business posted $4.96 earnings per share. On average, equities analysts forecast that Amgen will post 19.48 EPS for the current fiscal year.
Institutional Investors Weigh In On Amgen
A number of institutional investors and hedge funds have recently bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the 3rd quarter valued at about $25,000. Strategic Financial Concepts LLC acquired a new position in Amgen during the 2nd quarter valued at about $26,000. Hershey Financial Advisers LLC acquired a new stake in Amgen in the 2nd quarter valued at approximately $30,000. nVerses Capital LLC bought a new stake in shares of Amgen during the second quarter valued at about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new stake in shares of Amgen in the 2nd quarter worth approximately $33,000. Hedge funds and other institutional investors own 76.50% of the company's stock.
About Amgen
(
Get Free Report)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Amgen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.
While Amgen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
